Loading…
Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii
Summary Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to >99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This stu...
Saved in:
Published in: | Mycoses 2012-03, Vol.55 (2), p.156-160 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3 |
container_end_page | 160 |
container_issue | 2 |
container_start_page | 156 |
container_title | Mycoses |
container_volume | 55 |
creator | Saribas, Zeynep Yurdakul, Pinar Cetin-Hazirolan, Gulsen Arikan-Akdagli, Sevtap |
description | Summary
Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to >99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified. |
doi_str_mv | 10.1111/j.1439-0507.2011.02050.x |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_922500430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>922500430</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhS1ERZfCX0C-wSVhbCd2cuCAFiiVtuVSVOBiebN28eLYqZ3Abn89Dlv2iPDFM57vjfX0EMIESpLP621JKtYWUIMoKRBSAs11uXuEFsfBY7SAlrFCVCBO0dOUtgBEtJQ_QaeUcN7UtF6g-wtv3KR9p3EwOOk49Th4bD3-accYcJpSp4fRrq2z4x6POo3W386s7r5bHzrlN9YnbELEy7neKDyoqIZkXUg24fx2HNxO1jmrYx9yb5-hE6Nc0s8f7jP0-cP76-XHYvXp_GL5dlV02QoUBozgG8K0aWrD25orRiraCdpB1YAxBEhrGCFCVaZaC2ibSjOuDAWua7FW7Ay9POwdYribsgHZ22zKOeV1mJJsKa0BKgaZfPVPkgBtgFHGWUabA9rFkFLURg7R9iruMyTnjORWzlHIOQo5ZyT_ZCR3Wfri4Zdp3evNUfg3lAy8OQC_rNP7_14sL78u5yrri4PeplHvjnoVf0gumKjlzdW5bMW7b6svN9eyYb8By_ev_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1028032363</pqid></control><display><type>article</type><title>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Saribas, Zeynep ; Yurdakul, Pinar ; Cetin-Hazirolan, Gulsen ; Arikan-Akdagli, Sevtap</creator><creatorcontrib>Saribas, Zeynep ; Yurdakul, Pinar ; Cetin-Hazirolan, Gulsen ; Arikan-Akdagli, Sevtap</creatorcontrib><description>Summary
Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to >99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified.</description><identifier>ISSN: 0933-7407</identifier><identifier>EISSN: 1439-0507</identifier><identifier>DOI: 10.1111/j.1439-0507.2011.02050.x</identifier><identifier>PMID: 21668525</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antifungal Agents - metabolism ; Antifungal Agents - pharmacology ; Aspergillosis ; Aspergillosis - microbiology ; Aspergillus ; Aspergillus - drug effects ; Aspergillus - growth & development ; Aspergillus - isolation & purification ; Blood Proteins - metabolism ; Candida ; Candida - drug effects ; Candida - growth & development ; Candida - isolation & purification ; Candida guilliermondii ; Candida parapsilosis ; Candidiasis ; Candidiasis, Invasive - microbiology ; Caspofungin ; Clinical isolates ; Drugs ; echinocandins ; Echinocandins - metabolism ; Echinocandins - pharmacology ; Humans ; in vitro susceptibility testing ; micafungin ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Protein Binding ; Serum ; Serum proteins</subject><ispartof>Mycoses, 2012-03, Vol.55 (2), p.156-160</ispartof><rights>2011 Blackwell Verlag GmbH</rights><rights>2011 Blackwell Verlag GmbH.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</citedby><cites>FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21668525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saribas, Zeynep</creatorcontrib><creatorcontrib>Yurdakul, Pinar</creatorcontrib><creatorcontrib>Cetin-Hazirolan, Gulsen</creatorcontrib><creatorcontrib>Arikan-Akdagli, Sevtap</creatorcontrib><title>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</title><title>Mycoses</title><addtitle>Mycoses</addtitle><description>Summary
Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to >99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified.</description><subject>Antifungal Agents - metabolism</subject><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillosis</subject><subject>Aspergillosis - microbiology</subject><subject>Aspergillus</subject><subject>Aspergillus - drug effects</subject><subject>Aspergillus - growth & development</subject><subject>Aspergillus - isolation & purification</subject><subject>Blood Proteins - metabolism</subject><subject>Candida</subject><subject>Candida - drug effects</subject><subject>Candida - growth & development</subject><subject>Candida - isolation & purification</subject><subject>Candida guilliermondii</subject><subject>Candida parapsilosis</subject><subject>Candidiasis</subject><subject>Candidiasis, Invasive - microbiology</subject><subject>Caspofungin</subject><subject>Clinical isolates</subject><subject>Drugs</subject><subject>echinocandins</subject><subject>Echinocandins - metabolism</subject><subject>Echinocandins - pharmacology</subject><subject>Humans</subject><subject>in vitro susceptibility testing</subject><subject>micafungin</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Protein Binding</subject><subject>Serum</subject><subject>Serum proteins</subject><issn>0933-7407</issn><issn>1439-0507</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkUFv1DAQhS1ERZfCX0C-wSVhbCd2cuCAFiiVtuVSVOBiebN28eLYqZ3Abn89Dlv2iPDFM57vjfX0EMIESpLP621JKtYWUIMoKRBSAs11uXuEFsfBY7SAlrFCVCBO0dOUtgBEtJQ_QaeUcN7UtF6g-wtv3KR9p3EwOOk49Th4bD3-accYcJpSp4fRrq2z4x6POo3W386s7r5bHzrlN9YnbELEy7neKDyoqIZkXUg24fx2HNxO1jmrYx9yb5-hE6Nc0s8f7jP0-cP76-XHYvXp_GL5dlV02QoUBozgG8K0aWrD25orRiraCdpB1YAxBEhrGCFCVaZaC2ibSjOuDAWua7FW7Ay9POwdYribsgHZ22zKOeV1mJJsKa0BKgaZfPVPkgBtgFHGWUabA9rFkFLURg7R9iruMyTnjORWzlHIOQo5ZyT_ZCR3Wfri4Zdp3evNUfg3lAy8OQC_rNP7_14sL78u5yrri4PeplHvjnoVf0gumKjlzdW5bMW7b6svN9eyYb8By_ev_A</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Saribas, Zeynep</creator><creator>Yurdakul, Pinar</creator><creator>Cetin-Hazirolan, Gulsen</creator><creator>Arikan-Akdagli, Sevtap</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</title><author>Saribas, Zeynep ; Yurdakul, Pinar ; Cetin-Hazirolan, Gulsen ; Arikan-Akdagli, Sevtap</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antifungal Agents - metabolism</topic><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillosis</topic><topic>Aspergillosis - microbiology</topic><topic>Aspergillus</topic><topic>Aspergillus - drug effects</topic><topic>Aspergillus - growth & development</topic><topic>Aspergillus - isolation & purification</topic><topic>Blood Proteins - metabolism</topic><topic>Candida</topic><topic>Candida - drug effects</topic><topic>Candida - growth & development</topic><topic>Candida - isolation & purification</topic><topic>Candida guilliermondii</topic><topic>Candida parapsilosis</topic><topic>Candidiasis</topic><topic>Candidiasis, Invasive - microbiology</topic><topic>Caspofungin</topic><topic>Clinical isolates</topic><topic>Drugs</topic><topic>echinocandins</topic><topic>Echinocandins - metabolism</topic><topic>Echinocandins - pharmacology</topic><topic>Humans</topic><topic>in vitro susceptibility testing</topic><topic>micafungin</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Protein Binding</topic><topic>Serum</topic><topic>Serum proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saribas, Zeynep</creatorcontrib><creatorcontrib>Yurdakul, Pinar</creatorcontrib><creatorcontrib>Cetin-Hazirolan, Gulsen</creatorcontrib><creatorcontrib>Arikan-Akdagli, Sevtap</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Mycoses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saribas, Zeynep</au><au>Yurdakul, Pinar</au><au>Cetin-Hazirolan, Gulsen</au><au>Arikan-Akdagli, Sevtap</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</atitle><jtitle>Mycoses</jtitle><addtitle>Mycoses</addtitle><date>2012-03</date><risdate>2012</risdate><volume>55</volume><issue>2</issue><spage>156</spage><epage>160</epage><pages>156-160</pages><issn>0933-7407</issn><eissn>1439-0507</eissn><abstract>Summary
Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to >99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21668525</pmid><doi>10.1111/j.1439-0507.2011.02050.x</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0933-7407 |
ispartof | Mycoses, 2012-03, Vol.55 (2), p.156-160 |
issn | 0933-7407 1439-0507 |
language | eng |
recordid | cdi_proquest_miscellaneous_922500430 |
source | Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list) |
subjects | Antifungal Agents - metabolism Antifungal Agents - pharmacology Aspergillosis Aspergillosis - microbiology Aspergillus Aspergillus - drug effects Aspergillus - growth & development Aspergillus - isolation & purification Blood Proteins - metabolism Candida Candida - drug effects Candida - growth & development Candida - isolation & purification Candida guilliermondii Candida parapsilosis Candidiasis Candidiasis, Invasive - microbiology Caspofungin Clinical isolates Drugs echinocandins Echinocandins - metabolism Echinocandins - pharmacology Humans in vitro susceptibility testing micafungin Microbial Sensitivity Tests Minimum inhibitory concentration Protein Binding Serum Serum proteins |
title | Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A29%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20serum%20on%20in%20vitro%20susceptibility%20testing%20of%20echinocandins%20for%20Candida%20parapsilosis%20and%20Candida%20guilliermondii&rft.jtitle=Mycoses&rft.au=Saribas,%20Zeynep&rft.date=2012-03&rft.volume=55&rft.issue=2&rft.spage=156&rft.epage=160&rft.pages=156-160&rft.issn=0933-7407&rft.eissn=1439-0507&rft_id=info:doi/10.1111/j.1439-0507.2011.02050.x&rft_dat=%3Cproquest_cross%3E922500430%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1028032363&rft_id=info:pmid/21668525&rfr_iscdi=true |